DCE-MRI PET Bevacizumab Study in Rectal Cancer
NCT01426074
·
clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
OTHER
Sponsor class
Conditions
Rectal Cancer Patients
Interventions
DRUG:
Bevacizumab 5 mg/kg
Sponsor
Abramson Cancer Center at Penn Medicine